Tiefenbacher Pharmaceuticals successfully launches the anticoagulant Rivaroxaban on day one in Canada

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world. A key point here is that this applies to everyone, regardless of their nationality or income. That´s why we are thrilled to share that we have successfully prepared a day one launch of the generic version of the anticoagulant Rivaroxaban in Canada.

Generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. It makes blood flow through veins more easily by stopping a clotting factor called factor Xa from working. Rivaroxaban is also used to reduces the risk of stroke and systemic embolism with nonvalvular atrial fibrillation. The tablets are marketed in the strengths 2.5mg (for the very first time), 10mg, 15mg, and 20mg by our cooperation partner.

The product has been developed in TIEFENBACHER GROUP´s own laboratories in Hyderabad, India. Also it has already been launched in several European and international markets before. Overall, Tiefenbacher country scope covers about 70 countries around the world. Furthermore, the successful launch of this anticoagulant is a testament to the hard work and dedication of the team.

Finally, we are particularly excited about the positive impact of the launch of rivaroxaban and look forward to further market entries with high-quality medicines – with a patient-centred approach for better healthcare.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.  

For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at  info@tiefenbacher.com or visit us on  www.tiefenbacher-pharmaceuticals.com

Tiefenbacher New Market Launch: Rivaroxaban in Canada
About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com